AAV Packaging

Adeno-associated virus (AAV) has been an increasingly important viral vector for gene therapy and cell therapy. At Vigene Biosciences, we offer the world-class capability and capacity to provide AAV packaging services for all projects, large and small. We support small-scale AAV packaging for in vitro experimentation, large-scale AAV packaging required for successful studies involving animals, and services designed to go all the way to CGMP production for clinical trials and commercial production.

At Vigene Biosciences, our team of scientific experts will work with you to ensure that you receive AAV service that is customized to your research at every stage, meeting your needs quickly and efficiently.

What is AAV?

First discovered in 1965, human AAV was originally found in adenovirus preparations as a contaminant. It’s perhaps unsurprising that AAV was initially difficult to detect, since it’s one of the smallest viruses ever discovered, with a non-enveloped capsid of 22 nm.

AAV has never been associated with any particular disease, despite the fact that between 80% and 90% of adults test positive for AAV2, which is one of several serotypes. This aspect makes AAV one of the safest viral vectors available.

AAV serotypes occupy their own genus, Dependovirus, within the larger Parvoviridiae family. It has received this designation because AAV cannot initiate a productive infection without co-infection from a helper virus, such as herpes simplex or adenovirus.

Recombinant AAV (rAAV) is popular for its versatility, working well for both in vivo and in vitro cell delivery. This popularity as a vehicle for gene therapy is based primarily on the ability of rAAVs to transduce most mammalian cells regardless of type, as well as their very low human immunogenicity and non-pathogenicity.

 

The Vigene Difference

At Vigene Biosciences, we believe that quality production is key to ensuring the success of your experiments, which is why we have developed a number of proprietary methods to improve our production of recombinant AAV. This allows us to accurately produce rAAV with regard to potency, titer, consistency, and purity.

This has allowed us to serve projects of all sizes, from small-scale experiments to large-scale CGMP production that is safe for clinical trial purposes. Vigene Biosciences is one of the only companies that is able to offer this range of services, and we’re proud to do our part to support your experimental work.

 

Interested in AAV Packaging? Contact us today to request a quote >